Active transcutaneous bone conduction hearing implants: Systematic review and meta-analysis.
Astrid MagelePhilipp SchoergBarbara StanekBernhard GradlGeorg Mathias SprinzlPublished in: PloS one (2019)
The device's transcutaneous technology results in a minor event incidence rate of one in 9.9 person-years and a major incidence rate of one in 148.9 person-years. Based on the audiological outcomes, high patient satisfaction as well as the low complication rate, the authors recommend the active transcutaneous bone conduction hearing device as a safe and effective treatment for patients suffering from hearing loss within the device's indication criteria (conductive and/or mixed hearing loss or single-sided deafness).
Keyphrases
- hearing loss
- patient satisfaction
- end stage renal disease
- bone mineral density
- risk factors
- soft tissue
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- bone loss
- patient reported outcomes
- metabolic syndrome
- insulin resistance
- adipose tissue
- skeletal muscle
- reduced graphene oxide